EGRX Eagle Pharmaceuticals, Inc.: רווח למניה ב-12 החודשים האחרונים

Eagle Pharmaceuticals is engaged in a fierce battle for market share, facing competition from low-cost generics of its products. This pressure is further amplified by patent expiration risks and challenges in securing approvals for new products. However, the company is developing drug delivery methods to improve oncology therapy. This annual EPS TTM chart illustrates this trajectory, with the most recent value recorded as -49.60.
Eagle Pharma - פילוחים אנליטיים ומדדי מפתח (EGRX)

Year-over-year EPS growth (TTM) reflects the earnings per share dynamics over a rolling twelve-month period. This metric calculates the percentage change in net income, stripping out seasonal distortions. Analyzing the annual EPS growth over a rolling year allows for an assessment of the business's actual capitalization efficiency. For Eagle Pharmaceuticals (EGRX), this indicator confirms the monetization of exclusive drug delivery protocols. Steady growth here signals the reliability of the niche onco-hematology ecosystem.